Table 1.

Cytotoxic effect of NU6140 and purvalanol A against HeLa cells as single agents and in combination with paclitaxel

Agent/combinationConcentrationSurviving fraction
Expected/observed ratio*CI
ObservedExpected
Paclitaxel (nmol/L)10.76
2.50.34
50.12
NU6140 (μmol/L)10.70
2.50.47
50.14
Purvalanol A (μmol/L)10.97
2.50.89
50.75
Paclitaxel (nmol/L) + NU6140 (μmol/L)1
10.500.531.061.14
2.5
2.50.050.163.20.47
5
50.0020.02100.29
Paclitaxel (nmol/L) + purvalanol A (μmol/L)1
10.620.741.190.90
2.5
2.50.180.301.70.60
5
50.020.094.50.44
NU6140 (μmol/L) + paclitaxel (nmol/L)1
10.640.530.871.51
2.5
2.50.090.161.780.76
5
50.0120.021.670.45
Purvalanol A (μmol/L) + paclitaxel (nmol/L)1
10.660.741.120.95
2.5
2.50.180.301.670.70
5
50.030.093.000.53
  • * (Surviving fraction observed) / (surviving fraction expected).

  • CI according to Chou and Talalay (ref. 30).

  • Calculated as the product of the surviving fractions observed for individual drugs.